Pediatric Cancer & Blood Disorder Research

Revolutionary Research from the Lab to the Bedside

A crucial part of our mission at University Hospitals is to make significant scientific discoveries about blood disorders and cancers and integrate them into our patients’ care. Our research scientists collaborate with clinicians at the point of care. Together, we find new therapies, drugs and medical devices that will change the way cancer and blood disorders are treated and bring them rapidly to our patients, including:

University Hospitals Rainbow Babies & Children’s partners with the prestigious Case Comprehensive Cancer Center (CCC), part of Case Western Reserve University School of Medicine. Case CCC is designated by the National Cancer Institute as a comprehensive cancer center – one of only 49 in the U.S. to earn this distinction. We are the primary pediatric affiliate of Case CCC. Through this relationship, we are linked with other medical institutions in a stronger and more unified effort to understand the causes and progression of cancer. We use this understanding to develop new treatments for infants, children, adolescents and young adults with cancer and improve patient outcomes.

Our pediatric cancer and blood disorder team also works closely with University Hospitals’ own Harrington Discovery Institute. This is an international initiative dedicated to physician-scientists. Our scholars strive to transform breakthrough discoveries into new medicines.

Additional national partnerships and affiliations include:

Dr. John Letterio Talks About Chemoprevention

Access to More Clinical Trials and Innovative Therapies

Because of the strength in our research enterprise, our patients have access to new and promising treatment options. We are one of few sites in the world to offer the groundbreaking CAR T-cell therapy  to children and young adults with relapsed or refractory (resistant cancer). This highly advanced therapy modifies a patient’s own immune cells, so they can identify and fight deadly cancer cells.